Medical articles today

/* 728x15, */

Novel Biomarkers In Emotions Failure At Passion Failure Congress 2009

/* 468x60, */

Several fashionable biomarkers compass been recently described in Feelings Failure (HF) syndrome either in steady chronic patients as in the settings of acute decompensation. Biomarkers are used to diagnose disease risk, to predict outcome and to dressmaker treatment to individuals.
Speaking at a press conference at Heart Failure 2009 in Nice, France, Prof Piotr Ponikowski, spokesperson for the European Homeland of Cardiology, presented these contemporary findings, namely:
  • ST2 - a member of the interleukin (IL)-1 receptor family, markedly upregulated on the use of mechanical strain to cardiac myocytes; reported to be elevated in severe chronic HF, where independently predicts fortuneless outcome; serial monitoring in acute decompensated HF may be fine for risk stratification
  • ultrasensitive troponins reflecting damage/loss of cardiomyocytes; elevation in chronic HF identifies damaging outcome
  • fresh glycation end-products (AGEs) - molecules formed during a non-enzymatic reaction between proteins and sugar residues; there is an evidence that AGEs are related to the buildup and progression of HF in diabetic and non-diabetic patients;
  • adrenomedullin - hormone which is a potent vasodilator, with inotropic and natriuretic properties; assessment of mid-regional atom of the proadrenomedullin (MR-proADM test) has been proved to add more information on morals of disquiet in the diagnosis of acute HF and to be advantageous in prognostic analysis of these patients
  • estrogens - it has been recently shown that both low and altitudinous concentrations of circulating estradiol are powerful predictors of a wick prognosis in men with chronic HF; subjects with either reduced or increased concentrations of serum E2 have at odds clinical characteristics, suggesting that the underlying pathophysiological mechanisms are not the equivalent
"Biomarker" is a very wide phrase that refers to parameter reflecting or characterizing a persuaded biological process. It may contain cross-section of indices/parameters derived from clinical images, physiological tests, tissue biopsies, and even genetic variants, but most often, this term is reserved for blood or urine based assessments.
As examples of biomarkers assessed in the blood, which are already well established and widely used in clinical practice:
  • for lipid metabolism - blood cholesterol or LDL-cholesterol levels
  • for glucose metabolism - glycated haemoglobin (HbA1c)
  • for kidney avail - creatinine, or recently cystatin C
  • for inflammation - C-reactive protein (CRP)
  • for anaemia - hemoglobin
  • for cardiac advantage - natriuretic peptides
Biomarker assessments are used in many clinical scenarios, in the emergency department, on the ward, in the outpatient clinic and in the near future at the patient's down home (using telemedicine platform).
In affection failure, biomarkers aid in the diagnosis, support to assess co-morbidities in patients, may be useful in the risk stratification, monitoring of therapy and all the more serve as a therapeutic target. Importantly, assorted biomarkers may provide an insight into the pathophysiology of HF.
"The field of HF biomarkers continues to grow exponentially", explains Prof Ponikowski from Military Hospital in Wroclaw, Poland. "The closest is a new classification, recently proposed by Prof Eugene Braunwald, according to which biomarkers can reflect/characterize at variance aspects of HF:
  • inflammation
  • oxidative stress
  • extracellular-matrix remodeling
  • neurohormones
  • myocyte injury
  • myocyte stress"
ESC Press Job
European Country of Cardiology
View narcotic confidence on Estradiol.
/* 468x60, */


hf, chronic hf, hf diabetic, hf advantageous, hf independently, hf fine, hf syndrome, hf identifies, hf inflammation, hf subjects
/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy